论文部分内容阅读
目的对比观察重组人干扰素α-2b与炎琥宁注射液分别联合利巴韦林治疗小儿手足口病的临床疗效。方法将300例手足口病患儿随机分为A、B、C 3组,A组采用重组干扰素联合利巴韦林治疗,B组采用炎琥宁联合利巴韦林治疗,C组单用利巴韦林治疗。比较3组患儿临床疗效、症状消退及治愈时间,并观察各组患者心肌酶及超敏C反应蛋白(hs-CRP)。结果 A、B组治疗总有效率均高于C组,差异均有统计学意义(P<0.01);A组和B组总有效率相比差异无统计学意义(P>0.05);A组和B组临床症状消退及治愈时间均短于C组,差异均有统计学意义(P<0.05),A组和B组相比差异无统计学意义(P>0.05);治疗后,3组心肌酶、hs-CRP含量较治疗前明显降低,差异有统计学意义(P<0.01),且A、B组较C组明显降低(P<0.05),但A组和B组相比差异无统计学意义(P>0.05)。结论重组人干扰素α-2b联合利巴韦林、炎琥宁联合利巴韦林治疗手足口病效果较好,可降低心肌酶、hs-CRP含量,值得临床推广应用。
Objective To compare the clinical efficacy of recombinant human interferon α-2b and Yanhuning injection in combination with ribavirin in the treatment of children’s hand-foot-mouth disease. Methods 300 cases of hand, foot and mouth disease were randomly divided into A, B, C 3 groups, A group using recombinant interferon combined with ribavirin treatment, B group with Yan Hu Ning combined with ribavirin treatment, C group single use Ribavirin treatment. The clinical curative effect, symptom subsidence and cure time were compared between the three groups. The myocardial enzymes and hs-CRP in each group were also observed. Results The total effective rate in group A and group B was significantly higher than that in group C (P <0.01). There was no significant difference in total effective rate between group A and group B (P> 0.05) (P <0.05). There was no significant difference between group A and group B (P> 0.05). After treatment, group 3 The levels of myocardial enzymes and hs-CRP were significantly lower than those before treatment (P <0.01), and the A and B groups were significantly lower than those of C group (P <0.05), but there was no significant difference between A group and B group Statistical significance (P> 0.05). Conclusions Recombinant human interferon α-2b combined with ribavirin and mesylate combined with ribavirin is effective in treating hand-foot-mouth disease and can reduce the level of myocardial enzyme and hs-CRP, which deserves clinical application.